

UNITED STATES JUDICIAL PANEL  
on  
MULTIDISTRICT LITIGATION

IN RE: NATIONAL PRESCRIPTION OPIATE  
LITIGATION

MDL No. 2804

(SEE ATTACHED SCHEDULE)


**CONDITIONAL TRANSFER ORDER (CTO -181)**

On December 5, 2017, the Panel transferred 62 civil action(s) to the United States District Court for the Northern District of Ohio for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* 290 F.Supp.3d 1375 (J.P.M.L. 2017). Since that time, 2,073 additional action(s) have been transferred to the Northern District of Ohio. With the consent of that court, all such actions have been assigned to the Honorable Dan A. Polster.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Northern District of Ohio and assigned to Judge Polster.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Northern District of Ohio for the reasons stated in the order of December 5, 2017, and, with the consent of that court, assigned to the Honorable Dan A. Polster.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Northern District of Ohio. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.



FOR THE PANEL:



John W. Nichols  
Clerk of the Panel

**IN RE: NATIONAL PRESCRIPTION OPIATE  
LITIGATION**

MDL No. 2804

**SCHEDULE CTO-181 – TAG-ALONG ACTIONS**

**DIST      DIV.      C.A.NO.      CASE CAPTION**

ALABAMA MIDDLE

ALM	3	20-00976	City of Auburn, Alabama v. Amerisourcebergen Drug Corporation et al
-----	---	----------	---

MASSACHUSETTS

MA	1	20-12156	Town of Millis, MA v. Amerisourcebergen Drug Corporation et al
----	---	----------	--